About Kevin
Kevin Kruczynski is a Fund Manager in the Global Equities team. Kevin joined Liontrust in 2024 from GAM where he managed both Global and US Equity portfolios. He joined GAM Investments in 2016 from THS Partners, a global equity investment firm and a long-standing sub-advisor of GAM’s oldest global equity strategies. Prior to that, Kevin spent two years at Cazenove Capital and in 2001 he worked for Merrill Lynch Investment Managers, where he supported the charities team. Kevin holds a degree in Banking and International Finance from City University and is a CFA charterholder.
Latest insights
David Goodman
"AI is not going to take your job" — but people who know how to use it might
David Goodman explains why the narrative that “AI is coming for your job” misses the point and it is rather about humans using machines to outcompete one another.
Pieran Maru
Beyond classical: Quantum computing's leap
Quantum computing offers the promise of significant advancements in AI and machine learning across a wide range of fields. Pieran Maru analyses the potential impact of quantum computing and the opportunities for investors, as well as the possible challenges.
David Goodman
Poker and active investing
David Goodman looks at how active investing and poker share similarities in psychology, strategy and risk
Pieran Maru
AI Agents: Are they the new workforce?
Pieran Maru explains what AI Agents are, de-bunks some misconceptions and discusses who the winners and losers might be from their development
Kevin Kruczynski
The US prescription drug market is ripe for disruption
Research reveals that US drug prices are nearly 2.8 times higher than the average in comparable countries primarily due to patent protection and the absence of centralised negotiation capabilities. Kevin Krucynski discusses how to invest in potential disruptors in the market
